Kaléo

Hoping everyone has a safe and celebratory July 4th. #IndependenceDay #July4th #MedicalCountermeasures

We are proud to announce that Biomedical Advanced Research and Development Authority (BARDA) has selected Kaléo to develop the next generation pralidoxime chloride (2-PAM) auto-injector as a medical countermeasure against nerve agent poisoning. “The contract tasks Kaléo with developing a 2-PAM auto-injector for U.S. Food and Drug Administration (FDA) approval within 3 years, with an ultimate goal of enabling later procurement of the 2-PAM auto-injectors for BARDA’s CHEMPACK program,” said Mark Herzog, Kaleo’s VP for Global Corporate Affairs, Defense and Homeland Security. Kaléo is a market leader in emergency use auto-injectors with more than 12 million devices manufactured to meet the FDA’s standard of 99.999% device reliability. Read our full announcement here: https://bit.ly/2PAM_AI #Kaleo #MCM #medicalcountermeasure #CHEMPACK #BARDA #publichealth

Congratulation's to our 2023 Kaléo President's Club winners. Thank you for your dedication and passion helping to educate our healthcare parters and empower our patients. #pharmasales Anya Pelczarska Phil Brand Amanda Lovingood, RN, BSN Eric Schmieder Krissy Frye John Fetch Patrick Donovan Garrison Smith Jennifer Hauer Patrick Hollinger Kelli Arce Lance Griffin Skylar Langston Ed Schumacher Casey W.

We are teaming up with Brittany Mahomes, co-owner of the Kansas City Current soccer team and mom of two young children with food allergies, to raise awareness of life-threatening #FoodAllergies in young children. Learn more at https://bit.ly/B_Mahomes

The Kaléo team was proud to recently host the JPEO CBRN Medical team at our Richmond headquarters for the project launch for our next generation nerve agent countermeasure system.   #CBRN #Defense #WinningTeamwork

#KaléoEmployeeSpotlight series – we are excited to feature Dan Turner, Director, Commercial Data Solutions. Dan leads Kaléo’s data engineering, governance and analytic reporting functions. He loves working with a talented and passionate team and having the opportunity to harness Kaléo’s data assets to drive strategic decision-making and elevate business performance for our teams.

We are pleased to announce our selection by the U.S. Department of Defense to develop the Reconstitution Auto-Injector Device – Atropine (RAD-A). Our innovative reconstitution technology is expected to significantly extend the shelf life of the drug as well as its stability under extreme conditions. Read our announcement here: https://bit.ly/KaleoMCM #CBRN #MCM #medicalcountermeasure #defense